600276.SS Earnings — Jiangsu Hengrui Medicine Co., Ltd.

SHH

Updated Oct 28, 2026

Price —

Market Cap $308.5B

P/E 35.8

52W Range — – —

When is 600276.SS's next earnings date?

Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) has not announced its next earnings date yet. Its most recent earnings report was on Tuesday, October 27, 2026.

How did 600276.SS do in its last earnings report?

In its most recent report on Oct 27, 2026, Jiangsu Hengrui Medicine Co., Ltd. posted EPS of $0.37 versus the $0.33 estimate, a beat of 11.5%. Revenue was $8.90B against a $8.91B estimate.

How much does 600276.SS stock move after earnings?

600276.SS beat EPS estimates in 1 of its last 2 reported quarters.

About Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.

🤖 AI Earnings Analysis

Hengrui Medicine posted a modest earnings beat, with EPS of $0.37, $0.04 above consensus, while $8.9B revenue essentially matched estimates; absent growth or guidance detail, results look mixed for the pharmaceutical company.

AI-generated summary — powered by BigEarnings.